Abstract
Background. Congenital heart defects (CHD) are the most common type of developmental anomalies in children. At present the early diagnosis of congestive heart failure (CHF) and CHF-associated pathologic conditions is becoming increasingly important for optimization of protocols for following up pediatric patients in the primary health care settings.Objective. The study aimed at determining the prognostic role of brain natriuretic peptide (BNP) as a diagnostic marker of CHF progression and development of CHF-associated pathological conditions in babies with CHD during the first year of life.Methods. A prospective cohort study was carried out in a total of 114 children of the first year of life. The main study group was comprised of 61 children with confirmed diagnosis of CHD, and the control group of 53 health status group I–IIA children without CHD.Results. Diagnostic role of BNP elevation > 30 pg/mL was determined. At this BNP level the risk for developing stage 2A CHF increased 7-fold (OR 7.5 [1.8–31.5]), for developing functional class (FC) 2 CHF — nearly 5-fold (OR 4.6 [1.3–16.0]), and for FC 3 CHF such risk increased 9-fold (OR 9.2 [2.3–36.1]). Our results demonstrated that the BNP level measurements can be used in clinical practice to determine the likelihood of persistence of symptoms of perinatal CNS injuries during the first year of life (OR 7.6 [1.7–34.5]) and protein and energy deficit (PED) (OR 9.5 [2.5–35.5]) in children with CHD.
Highlights
Congenital heart defects (CHD) are the most common type of developmental anomalies in children
At present the early diagnosis of congestive heart failure (CHF) and CHF-associated pathologic conditions is becoming increasingly important for optimization of protocols for following up pediatric patients in the primary health care settings
The study aimed at determining the prognostic role of brain natriuretic peptide (BNP) as a diagnostic marker of CHF progression and development of CHF-associated pathological conditions in babies with CHD during the first year of life
Summary
ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России, Екатеринбург, Российская Федерация. Цель исследования: определить прогностическую роль мозгового натрийуретического пептида (BNP) в качестве маркера прогрессирования ХСН и развития патологических состояний, ассоциированных с течением ХСН, у детей первого года жизни с ВПС. Включавшее наблюдение 114 детей первого года жизни. Продемонстрировано, что уровень BNP можно использовать в клинической практике для определения вероятности персистенции на первом году жизни симптомов перинатального поражения ЦНС (OR7,6 [1,7–34,5]) и белково-энергетической недостаточности (OR9,5 [2,5–35,5]) у детей с ВПС. Прогностическая роль мозгового натрийуретического пептида у детей первого года жизни с врожденными пороками сердца: проспективное когортное исследование. Цель исследования Целью настоящего исследования было определить прогностическую роль BNP в качестве маркера прогрессирования ХСН и развития патологических состояний, ассоциированных с течением ХСН, у детей первого года жизни с ВПС.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
